BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $91.00

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price objective increased by Morgan Stanley from $88.00 to $91.00 in a report issued on Friday,Benzinga reports. They currently have an overweight rating on the stock.

BBIO has been the subject of a number of other reports. Weiss Ratings cut shares of BridgeBio Pharma from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, September 25th. Mizuho lifted their price objective on BridgeBio Pharma from $96.00 to $110.00 and gave the stock an “outperform” rating in a report on Tuesday, September 1st. Canaccord Genuity Group increased their price objective on shares of BridgeBio Pharma from $106.00 to $108.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. UBS Group reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research note on Friday, October 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, October 5th. Nineteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.42.

Read Our Latest Report on BridgeBio Pharma

BridgeBio Pharma Stock Performance

BridgeBio Pharma stock opened at $78.30 on Friday. BridgeBio Pharma has a 1-year low of $62.50 and a 1-year high of $93.42. The firm’s fifty day simple moving average is $69.98 and its 200-day simple moving average is $72.79. The company has a market capitalization of $15.25 billion, a P/E ratio of -25.76 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.12. The business had revenue of $353.17 million during the quarter, compared to the consensus estimate of $293.47 million. The company’s revenue for the quarter was up 192.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.95) earnings per share. On average, equities research analysts predict that BridgeBio Pharma will post -2.55 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Neil Kumar sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the transaction, the chief executive officer directly owned 495,686 shares in the company, valued at $34,241,988.88. This represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $72.85, for a total value of $145,700.00. Following the completion of the transaction, the chief accounting officer directly owned 120,687 shares in the company, valued at approximately $8,792,047.95. This trade represents a 1.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 56,980 shares of company stock valued at $4,563,699. 14.23% of the stock is currently owned by insiders.

Institutional Trading of BridgeBio Pharma

Hedge funds have recently added to or reduced their stakes in the business. Jump Financial LLC acquired a new stake in shares of BridgeBio Pharma during the third quarter worth about $304,000. Marshall Wace LLP boosted its holdings in BridgeBio Pharma by 43.0% during the third quarter. Marshall Wace LLP now owns 393,946 shares of the company’s stock worth $25,922,000 after purchasing an additional 118,430 shares during the last quarter. Empowered Funds LLC bought a new position in shares of BridgeBio Pharma in the 3rd quarter valued at about $8,689,000. State Board of Administration of Florida Retirement System increased its position in shares of BridgeBio Pharma by 0.8% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 109,970 shares of the company’s stock worth $7,236,000 after purchasing an additional 844 shares during the last quarter. Finally, Meeder Advisory Services Inc. bought a new stake in BridgeBio Pharma during the third quarter worth $239,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.

Further Reading

Analyst Recommendations for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.